BioCryst Selects Two Plasma Kallikrein Inhibitors for Hereditary Angioedema into Preclinical Development
December 18, 2013 at 07:09 AM EST
BioCryst Pharmaceuticals (NASDAQ: BCRX ) today announced that it has selected two optimized plasma kallikrein inhibitors to advance into preclinical development as potential once-daily, oral treatments for the
